Exelixis Latest News. See Also: TransMedics Group May Improve on Heart Transplants

Exelixis Latest News

The latest news announced by Exelixis (EXEL) is the FDA acceptance of its New Drug Application (NDA) that evaluates the safety, tolerability, pharmacokinetics and preliminary antitumor activity of the firm’s investigational product XB002 in advanced solid tumors.

XB002 is an antibody-drug conjugate (ADC) composed of a human monoclonal antibody against tissue factor. After binding to tissue factor on tumor cells, XB002 is internalized and the cytotoxic agent released resulting in targeted tumor cell death. XB002 is a rationally designed next-generation ADC that leverages proprietary linker-payload technology.

As a next-generation tissue factor-targeting, antibody-drug conjugate, XB002 has demonstrated the potential for an improved therapeutic index and may provide a favorable safety profile compared with earlier-generation antibody-drug conjugates targeting tissue factors.

Leave a Reply